EGFR and non-small cell lung carcinoma: The introduction of tyrosine kinase inhibitors (TKIs) for non-small cell lung cancer (NSCLC) has greatly improved treatment outcomes in patients with epidermal growth factor receptor (EGFR) mutations [1,2,3].